FDA dos EUA aprova tDCS entregue em casa para o tratamento de depressão.
PMID: 41475514 ·
M, a, r, o, m, , B, i, k, s, o, n, ;, , A, n, d, r, e, , R, , B, r, u, n, o, n, i, ;, , M, a, r, k, , S, , G, e, o, r, g, e
Publicidade
Resumo
On Dec 8, 2025, the US Food and Drug Administration (FDA) approved the Flow Neuroscience transcranial Direct Current Stimulation (tDCS) device for the treatment of "moderate to severe major depressive disorder (MDD) in the current episode, either as monotherapy or as an adjunctive treatment, in patients 18 years and older who are not considered treatment refractory to medication." This represents the first FDA premarket approval (PMA) for a home-use non-invasive brain-stimulation device specific
Publicidade
Fonte oficial
Ver no PubMed →Dados provenientes do PubMed / NCBI. Para consultar o texto integral e as informações mais recentes, recorra sempre ao registo oficial.